The future of PSMA-targeted radionuclide therapy: An overview of recent preclinical research
Prostate specific membrane antigen (PSMA) has become a major focus point in the research and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled tracers. PSMA has shown to be an excellent target for PCa theranostics because of its high expression on the membrane of PCa cells and the increase in expression during disease progression. Therefore, numerous PSMA-targeting tracers have been developed and (pre)clinically studied with promising results. However, many of these PSMA-targeting tracers show uptake in healthy organs such as the salivary glands, causing radiotoxicity. Furthermore, not all patients respond to PSMA-targeted radionuclide therapy (TRT). This created the necessity of additional preclinical research studies in which existing tracers are reevaluated and new tracers are developed in order to improve PSMA-TRT by protecting the (PSMA-expressing) healthy organs and improving tumor uptake. In this review we will give an overview of the recent preclinical research projects regarding PCa-TRT using PSMA-specific radiotracers, which will give an indication of where the PSMA-TRT research movement is going and what we can expect in future clinical trials.
|Keywords||Prostate cancer, Prostate specific membrane antigen, Targeted radionuclide therapy|
|Persistent URL||dx.doi.org/10.3390/pharmaceutics11110560, hdl.handle.net/1765/120935|
Ruigrok, E.A.M. (Eline A. M.), van Weerden, W.M, Nonnekens, J, & de Jong, M. (2019). The future of PSMA-targeted radionuclide therapy: An overview of recent preclinical research. Pharmaceutics (Vol. 11). doi:10.3390/pharmaceutics11110560